SCHEMBL6153718

SCHEMBL6153718

CC(=O)OC(CC(=O)O)CC(=O)O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.67
SMN1; SMN2 Q16637 1/20 0.67
ALOX15 P16050 1/20 0.54
MMP12 P39900 1/20 0.50
CYP1A2 P05177 4/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
HRH1 P35367 1/20 0.45
TSHR P16473 3/20 0.43
PGD P52209 1/20 0.40
SLC22A6 Q4U2R8 1/20 0.39
CHRM2 P08172 1/20 0.38
CHRM4 P08173 1/20 0.38
CHRM1 P11229 1/20 0.38
TBXA2R P21731 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
MAPK1 P28482 2/20 0.37
GMNN O75496 1/20 0.37
HSP90AA1 P07900 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10414980 0.88 LMNA (0.60) LMNASMN1; SMN2ALOX15MMP12CYP1A2
SCHEMBL10712935 0.87 LMNA (0.55) LMNASMN1; SMN2ALOX15MMP12CYP1A2
SCHEMBL4928056 0.86 LMNA (0.58) LMNASMN1; SMN2ALOX15MMP12CYP1A2
SCHEMBL13229795 0.86 LMNA (0.58) LMNASMN1; SMN2ALOX15MMP12CYP1A2
SCHEMBL4923280 0.86 LMNA (0.58) LMNASMN1; SMN2ALOX15MMP12CYP1A2
SCHEMBL4923275 0.86 LMNA (0.58) LMNASMN1; SMN2ALOX15MMP12CYP1A2
SCHEMBL27535340 0.84 LMNA (0.56) LMNASMN1; SMN2ALOX15MMP12CYP1A2
SCHEMBL31571128 0.84 LMNA (0.56) LMNASMN1; SMN2ALOX15MMP12CYP1A2
SCHEMBL6036839 0.84 LMNA (0.51) LMNASMN1; SMN2ALOX15MMP12CYP1A2
SCHEMBL5175797 0.84 LMNA (0.51) LMNASMN1; SMN2ALOX15MMP12CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2014140006-A1 PROCESS FOR ENANTIOSELECTIVE SYNTHESIS OF 3-HYDROXY-GLUTARIC ACID MONOESTERS AND USE THEREOF SANDOZ AG (CH) 2014-09-18 WO disclosed
US-20050119341-A1 3-substituted oxyglutaric diester compound, optically active 3-substituted oxyglutaric monoester compound, and processes for producing these UBE INDUSTRIES, LTD. (JP) 2005-06-02 US disclosed
EP-1500642-A1 3-SUBSTITUTED OXYGLUTARIC DIESTER COMPOUND, OPTICALLY ACTIVE 3-SUBSTITUTED OXYGLUTARIC MONOESTER COMPOUND, AND PROCESSES FOR PRODUCING THESE Ube Industries, Ltd. (JP) 2005-01-26 EP disclosed
US-20020127577-A1 Bioactive sensors GRAFFINITY PHARMACEUTICALS AG (DE) 2002-09-12 US disclosed
EP-0168480-A4 PROCESS FOR PREPARING OPTICALLY-ACTIVE 4-AMINO-3-HYDROXYBUTYRIC ACID. WISCONSIN ALUMNI RES FOUND (US) 1987-10-08 EP disclosed
US-4584270-A ENZYME CLEAVAGE OF ESTER GROUPING OF 3-HYDROXYGLUTARIC ACID DIESTER, FOLLOWED BY CHEMICAL CONVERSION WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 1986-04-22 US disclosed
EP-0168480-A1 PROCESS FOR PREPARING OPTICALLY-ACTIVE 4-AMINO-3-HYDROXYBUTYRIC ACID WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 1986-01-22 EP disclosed
WO-1985003307-A1 PROCESS FOR PREPARING OPTICALLY-ACTIVE 4-AMINO-3-HYDROXYBUTYRIC ACID WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 1985-08-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119341-A1 3-substituted oxyglutaric diester compound, optically active 3-substituted oxyglutaric monoester compound, and processes for producing these OGDH, GLUL, ADSL LMNA 4022/4885SMN1; SMN2 4749/4885ALOX15 1313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.